Advocacy Priorities

Thank you for joining with thousands of other CCFA advocates across the nation who are helping us shape the policies and programs that impact people living with Inflammatory Bowel Disease (IBD).

Below are our advocacy priorities. Print out easy to use one pagers:

We are asking the U.S. Congress to support the following:


Join the Congressional Crohn's and Colitis Caucus
The Congressional Crohn's and Colitis Caucus is a bi-partisan group of Members of Congress that work together to raise awareness of Inflammatory Bowel Diseases (IBD), support IBD medical research, and protect patient access to care. The Caucus is led in the House by Representatives Ander Crenshaw (R-FL-4) and Nita Lowey (D-NY-17).

Access to Care

Co-Sponsor HR 1600, the Patients' Access to Treatments Act
HR 1600 would enable patients to better afford the medications they need by imposing limits on cost-sharing in insurance plans. It would prohibit higher cost-sharing for specialty medications than for other prescription drugs in non-preferred tiers. HR 1600 is estimated to increase insurance premiums by $3, a nominal cost.


Provide $1 million for the CDC IBD Epidemiology Program in FY17
The Centers for Disease Control and Prevention (CDC) should complement the existing IBD Epidemiology Study with research on IBD’s impact on minority and underserved populations. The study’s goal is to learn more about the causes, variations, and other factors of IBD in order to improve care and target interventions.

Provide $34.5 billion for NIH and $2.165 billion for NIDDK in FY17
Hope for more effective treatments and a cure for IBD lies in biomedical research. CCFA joins other stakeholders in recommending $34.5 billion for the National Institutes of Health NIH) in FY17 as well as an increase for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the lead institute for IBD research at NIH.

Include 'Inflammatory Bowel Diseases' in the DOD Peer-Reviewed Medical Research Program in FY17
'Inflammatory Bowel Diseases' has been included in the Department of Defense (DOD) Peer-Reviewed Medical Research Program since FY08, and IBD researchers consistently compete successfully. IBD is associated with service in the Persian Gulf and the prevalence of IBD is increasing among veterans.


Biological therapies have been revolutionary for IBD patients by helping to prevent surgery and hospitalization while improving quality of life for these patients. Access to biological therapies, is therefore, a crucial component of medical therapy for our patients. The entrance of biosimilars into the markets would create additional flexibility for patients and providers. Currently, the Food and Drug Administration (FDA) is developing a regulatory approval pathway for biosimilars, and states are updating older state laws on drug substitution. As policies on biosimilars are crafted, CCFA wants to ensure drug safety, limit the risk of immunogenicity, and create transparency between the patient, provider, and payer around the decisions related to switching to a biosimilar. For additional information, download CCFA's position statement on biosimilars, endorsed by NASPGHAN.

Other resources: